These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17478392)

  • 1. Successful treatment of psoriatic nails with low-dose cyclosporine administration.
    Syuto T; Abe M; Ishibuchi H; Ishikawa O
    Eur J Dermatol; 2007; 17(3):248-9. PubMed ID: 17478392
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris.
    Hashizume H; Ito T; Yagi H; Takigawa M; Kageyama H; Furukawa F; Hata M; Shirahama S; Tanaka M; Higashishiba T; Machida H; Tsushima T; Matsushita K
    J Dermatol; 2007 Jul; 34(7):430-4. PubMed ID: 17584318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis.
    Yoon HS; Youn JI
    J Dermatolog Treat; 2007; 18(5):286-90. PubMed ID: 17852632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of psoriatic trachyonychia during low-dose cyclosporin A treatment: a pilot study on onychochronobiology using optical profilometry.
    Piérard GE; Piérard-Franchimont C
    Dermatology; 1996; 192(2):116-9. PubMed ID: 8829491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of quality of life and clinical usefulness of cyclosporin administration in patients with nail psoriasis.
    Abe M; Syuto T; Yokoyama Y; Ishikawa O
    J Dermatol; 2011 Sep; 38(9):916-8. PubMed ID: 21352333
    [No Abstract]   [Full Text] [Related]  

  • 6. Topically applied fluorouracil in the treatment of psoriatic nails.
    Fredriksson T
    Arch Dermatol; 1974 Nov; 110(5):735-6. PubMed ID: 4418256
    [No Abstract]   [Full Text] [Related]  

  • 7. Cutaneous vascular alterations in psoriatic patients treated with cyclosporine.
    Stinco G; Lautieri S; Valent F; Patrone P
    Acta Derm Venereol; 2007; 87(2):152-4. PubMed ID: 17340023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preprandial vs. postprandial pharmacokinetics of cyclosporine in patients with psoriasis.
    Umezawa Y; Mabuchi T; Ozawa A
    Int J Dermatol; 2007 Aug; 46(8):880-2. PubMed ID: 17651179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
    Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
    Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal time for therapeutic drug monitoring of cyclosporine microemulsion in patients with psoriasis.
    Umezawa Y; Ozawa A
    Int J Dermatol; 2007 Jul; 46(7):763-6. PubMed ID: 17614813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term treatment with cyclosporin in severe psoriasis: four years of experience.
    Garcovich A; Gatti M; Pompili A; Olivetti G; Catamo F
    Acta Derm Venereol Suppl (Stockh); 1994; 186():92-3. PubMed ID: 8073852
    [No Abstract]   [Full Text] [Related]  

  • 12. [Experience with gelatin treatment of nail growth disorders].
    Patiri C
    Z Haut Geschlechtskr; 1971 Sep; 46(18):523-6. PubMed ID: 5094002
    [No Abstract]   [Full Text] [Related]  

  • 13. Instability of topical ciclosporin emulsion for nail psoriasis.
    Prins AM; Vos K; Franssen EJ
    Dermatology; 2007; 215(4):362-3. PubMed ID: 17911999
    [No Abstract]   [Full Text] [Related]  

  • 14. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis.
    Chaidemenos GC; Mourellou O; Avgoustinaki N; Papakonstantinou M; Karakatsanis G; Katsambas A
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1203-8. PubMed ID: 17894706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ophthalmic cyclosporine for the treatment of psoriatic conjunctivitis.
    Habeshian KA; Levitt JO
    J Am Acad Dermatol; 2014 Aug; 71(2):e43-4. PubMed ID: 25037807
    [No Abstract]   [Full Text] [Related]  

  • 16. Selected cytokines and acute phase proteins in psoriatic patients treated with cyclosporin A or Re-PUVA methods.
    Chodorowska G; Czelej D; Juszkiewicz-Borowiec M; Pietrzak A; Wojnowska D; Krasowska D
    Ann Univ Mariae Curie Sklodowska Med; 1999; 54():173-80. PubMed ID: 11205760
    [No Abstract]   [Full Text] [Related]  

  • 17. Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection.
    Cassano N; Vena GA
    Int J Dermatol; 2008 Sep; 47(9):980-1. PubMed ID: 18937672
    [No Abstract]   [Full Text] [Related]  

  • 18. Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study.
    Jacobi A; Braeutigam M; Mahler V; Schultz E; Hertl M
    Dermatology; 2008; 216(2):133-6. PubMed ID: 18216475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A possible role for low-dose cyclosporine in refractory immune thrombocytopenic purpura.
    Emilia G; Luppi M; Morselli M; Forghieri F; Potenza L; Torelli G
    Haematologica; 2008 Jul; 93(7):1113-5. PubMed ID: 18508788
    [No Abstract]   [Full Text] [Related]  

  • 20. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry.
    Nast A; Reytan N; Rosumeck S; Erdmann R; Rzany B
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1337-42. PubMed ID: 18624864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.